Related references
Note: Only part of the references are listed.
Article
Immunology
Brian Grunau et al.
Summary: This study compared the serology results of paramedics vaccinated with mRNA vaccines at short and long intervals, and found that a long dosing interval resulted in higher antibody concentrations.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Immunology
Victoria G. Hall et al.
Summary: Delayed dosing intervals can enhance immune response to COVID-19 vaccination, including virus neutralization against wild-type and variant viruses. This finding has significant implications for the global implementation of vaccines.
Article
Medicine, General & Internal
R. L. Atmar et al.
Summary: This study investigated the efficacy of homologous and heterologous booster vaccines in adults who had completed a primary Covid-19 vaccine regimen. The results showed that both types of booster vaccines were safe and immunogenic.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Immunology
Kristin L. Andrejko et al.
Summary: Vaccination with mRNA-based vaccines in California has shown to effectively prevent documented SARS-CoV-2 infections, with similar effectiveness for BNT126b2 and mRNA-1273. However, vaccine hesitancy poses a challenge in achieving the necessary coverage levels for herd immunity.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Immunology
Shiraz El Adam et al.
Summary: Among healthcare workers in British Columbia, Canada, single-dose and two-dose mRNA vaccines were found to have effectiveness rates of 71% and 90% respectively against SARS-CoV-2 infection. The protection provided by two doses of the vaccine was sustained for at least 7 months and supported the idea of extending the dosing interval.
OPEN FORUM INFECTIOUS DISEASES
(2022)
Article
Biochemistry & Molecular Biology
Rebecca P. Payne et al.
Summary: The study demonstrates that the first dose of the BNT162b2 mRNA vaccine can induce protection against the B.1.1.7 variant within weeks, and extending the interval between doses can result in higher levels of neutralizing antibody response. Prior infection with the virus can accelerate the immune response.
Article
Medicine, General & Internal
Sara Y. Tartof et al.
Summary: This study aimed to assess the overall and variant-specific effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19-related hospital admissions among members of a healthcare system in California. The effectiveness of the vaccine remained high against hospital admissions even up to 6 months after full vaccination, despite a decline in effectiveness against SARS-CoV-2 infections over time, which was likely due to waning immunity rather than the delta variant escaping vaccine protection.
Article
Biochemistry & Molecular Biology
Koen B. Pouwels et al.
Summary: A large, community-based study in the United Kingdom indicates that the effectiveness of BNT162b2 and ChAdOx1 vaccines against SARS-CoV-2 infections with symptoms or high viral burden is reduced with the Delta variant compared to the Alpha variant. Although the effectiveness of two doses is at least as great as protection afforded by prior natural infection, there are significant differences in the dynamics of immunity after the second dose between BNT162b2 and ChAdOx1.
Article
Medicine, General & Internal
Yair Goldberg et al.
Summary: The immunity against the delta variant of SARS-CoV-2 waned in all age groups in Israel a few months after receiving the second dose of the vaccine, leading to an increase in infection and severe cases.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Lindsey R. Baden et al.
Summary: Participants who had previously received placebo in the trial were offered the mRNA-1273 vaccine in the open-label phase. The incidence of Covid-19 in this group was lower than those who had been vaccinated earlier, showing a modest decrease in vaccine efficacy over time.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Hiam Chemaitelly et al.
Summary: In a study conducted in Qatar involving over 900,000 participants, vaccine effectiveness peaked at 77.5% in the first month after the second dose. However, it declined afterwards to as low as 20% in months 5 through 7 after vaccination, while protection against severe Covid-19 remained above 90% for at least 6 months.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Merryn Voysey et al.
Summary: The AZD1222 vaccine has been approved for emergency use in the UK with an interval of 4-12 weeks between doses. Analysis shows that the vaccine is efficacious with two doses and provides immunoprotection after the first dose before the second dose is administered.
Article
Multidisciplinary Sciences
Gayatri Amirthalingam et al.
Summary: The UK extended the interval between COVID-19 vaccine doses to 12 weeks, leading to higher antibody levels and estimated greater vaccine effectiveness. This study highlights the importance of an extended vaccine schedule in enhancing protection against COVID-19.
NATURE COMMUNICATIONS
(2021)
Article
Medicine, General & Internal
Xinxue Liu et al.
Summary: Heterologous prime-boost COVID-19 vaccine schedules could facilitate mass immunisation, with ChAd/BNT showing non-inferior immunogenicity compared to ChAd/ChAd, but BNT/ChAd did not demonstrate non-inferiority to BNT/BNT. The results support flexibility in using heterologous prime-boost vaccination with ChAd and BNT COVID-19 vaccines.
Article
Biochemistry & Molecular Biology
Joana Barros-Martins et al.
Summary: A study found that booster vaccination with BNT162b2 in healthcare professionals previously vaccinated with ChAdOx-1 nCoV-19 elicited more neutralizing antibodies and higher frequencies of virus-specific T cells. Additionally, BNT162b2 induced high titers of neutralizing antibodies against variants of concern, such as B.1.1.7, B.1.351, and P.1.
Article
Medicine, General & Internal
M. G. Thompson et al.
Summary: A study with a test-negative design analyzed 41,552 admissions to 187 hospitals and 21,522 visits to 221 EDs or urgent care clinics. The mRNA-based vaccines (>= 14 days after the second dose) were highly effective against SARS-CoV-2 infection leading to hospitalization (89%), ICU admission (90%), or an urgent care visit (91%).
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
H. M. El Sahly et al.
Summary: The mRNA-1273 vaccine demonstrated high efficacy in preventing COVID-19 illness and severe disease, with more than 5 months of protection and a good safety profile, including protection against asymptomatic infection.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Danuta M. Skowronski et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
